US Stock MarketDetailed Quotes
ALLO Allogene Therapeutics
- 3.040
- -0.330-9.79%
Close Apr 24 16:00 ET
- 3.040
- 0.0000.00%
Post 18:57 ET
519.00MMarket Cap-1454P/E (TTM)
3.420High3.030Low2.11MVolume3.370Open3.370Pre Close6.54MTurnover1.87%Turnover RatioLossP/E (Static)170.72MShares6.89052wk High1.01P/B342.40MFloat Cap2.23052wk Low--Dividend TTM112.63MShs Float55.000Historical High--Div YieldTTM11.57%Amplitude2.230Historical Low3.101Avg Price1Lot Size
Allogene Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -7.81%-237.73M | 13.51%-53.71M | -16.53%-55.53M | -45.44%-61.86M | 2.34%-66.64M | -19.32%-220.52M | -36.67%-62.1M | 2.50%-47.66M | -3.31%-42.53M | -38.33%-68.24M |
| Net income from continuing operations | 3.86%-327.27M | 13.03%-89.26M | 26.26%-61.32M | -4.28%-77.99M | -23.61%-98.7M | -86.99%-340.41M | -119,436.05%-102.63M | -6.35%-83.15M | -5.43%-74.79M | -141.86%-79.85M |
| Operating gains losses | -17.16%10.67M | -63.92%3.22M | 175.45%4.55M | 181.42%1.21M | -55.45%1.69M | 214.99%12.88M | 283.99%8.92M | 81.52%1.65M | -380.26%-1.49M | 1,069.23%3.8M |
| Depreciation and amortization | -0.67%14.2M | 13.33%3.48M | -7.46%3.57M | -0.87%3.64M | -5.01%3.51M | 36.74%14.3M | -27.68%3.07M | 65.67%3.86M | 87.12%3.68M | 92.49%3.69M |
| Other non cash items | -75.14%579K | -44.85%75K | -73.42%147K | -87.22%150K | -55.58%207K | 103.18%2.33M | 100.18%136K | 142.54%553K | 203.36%1.17M | -76.78%466K |
| Change In working capital | -492.74%-15.31M | -130.91%-3.4M | -291.20%-14.89M | -186.19%-4.4M | 136.91%7.38M | 112.20%3.9M | 33,242.42%11M | 131.07%7.79M | 30.28%5.1M | 49.09%-19.99M |
| -Change in prepaid assets | -56.85%1.09M | -146.34%-2.47M | -61.61%2.19M | 105.54%102K | 118.93%1.26M | -21.32%2.52M | -0.45%5.33M | 216.22%5.7M | -191.41%-1.84M | -1,001.76%-6.67M |
| -Change in payables and accrued expense | -316.44%-14.32M | -100.26%-16K | -663.81%-16.68M | -161.18%-4.37M | 170.59%6.74M | 129.36%6.62M | 226.25%6.08M | -67.41%2.96M | 684.92%7.14M | -5,796.91%-9.55M |
| -Change in other current assets | 56.36%-1.46M | -740.65%-1.03M | 10.29%-366K | -132.15%-100K | 101.45%45K | -416.10%-3.33M | -135.65%-123K | -23.26%-408K | 123.74%311K | -289.74%-3.11M |
| -Change in other current liabilities | 67.53%-611K | -351.43%-528K | 92.90%-37K | 101.39%13K | 90.71%-59K | -306.81%-1.88M | 117.77%210K | 1.70%-521K | -132.12%-936K | -117.47%-635K |
| -Change in other working capital | 85.71%-3K | 232.65%646K | -86.79%7K | -110.23%-44K | -3,500.00%-612K | 99.95%-21K | -247.58%-487K | -11.67%53K | 551.52%430K | 99.96%-17K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -7.81%-237.73M | 13.51%-53.71M | -16.53%-55.53M | -45.44%-61.86M | 2.34%-66.64M | -19.32%-220.52M | -36.67%-62.1M | 2.50%-47.66M | -3.31%-42.53M | -38.33%-68.24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 53.82%163.29M | 36.02%67.46M | -237.59%-34.27M | -68.24%17.16M | 604.69%112.94M | -35.13%106.16M | 69.56%49.6M | 91.39%24.91M | 119.70%54.03M | -123.12%-22.38M |
| Net PPE purchase and sale | 70.80%-1.52M | 89.30%-181K | 94.62%-12K | 79.04%-288K | 45.58%-1.04M | 75.80%-5.19M | -129.89%-1.69M | 93.34%-223K | 87.40%-1.37M | 70.56%-1.9M |
| Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 48.01%164.81M | 31.88%67.64M | -236.32%-34.26M | -68.51%17.45M | 656.63%113.97M | -45.10%111.35M | 61.50%51.29M | 53.59%25.13M | 56.10%55.41M | -117.18%-20.48M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 53.82%163.29M | 36.02%67.46M | -237.59%-34.27M | -68.24%17.16M | 604.69%112.94M | -35.13%106.16M | 69.56%49.6M | 91.39%24.91M | 119.70%54.03M | -123.12%-22.38M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,143.90%95.7M | 236.96%155K | 301.97%4.29M | 372,916.67%89.52M | -4.58%1.73M | -75.34%2.95M | -85.71%46K | -55.27%1.07M | -99.25%24K | -69.99%1.81M |
| Net common stock issuance | --91.11M | --0 | --3.19M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 55.36%4.58M | 236.96%155K | 2.35%1.09M | 6,591.67%1.61M | -4.58%1.73M | -75.34%2.95M | -85.71%46K | -55.27%1.07M | -99.25%24K | -69.99%1.81M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,143.90%95.7M | 236.96%155K | 301.97%4.29M | 372,916.67%89.52M | -4.58%1.73M | -75.34%2.95M | -85.71%46K | -55.27%1.07M | -99.25%24K | -69.99%1.81M |
| Net cash flow | ||||||||||
| Beginning cash position | -60.68%72.2M | -6.04%79.54M | 55.22%165.05M | 26.81%120.22M | -60.68%72.2M | -4.77%183.61M | -57.56%84.65M | -54.35%106.33M | -61.51%94.81M | -4.77%183.61M |
| Current changes in cash | 119.07%21.25M | 211.69%13.91M | -294.36%-85.51M | 288.89%44.83M | 154.08%48.03M | -1,111.77%-111.41M | 21.50%-12.45M | 35.24%-21.68M | 186.27%11.53M | -265.94%-88.8M |
| End cash Position | 29.44%93.45M | 29.44%93.45M | -6.04%79.54M | 55.22%165.05M | 26.81%120.22M | -60.68%72.2M | -60.68%72.2M | -57.56%84.65M | -54.35%106.33M | -61.51%94.81M |
| Free cash flow | -6.00%-239.25M | 15.52%-53.89M | -16.01%-55.54M | -41.54%-62.15M | 3.51%-67.67M | -9.43%-225.71M | -38.15%-63.79M | 8.32%-47.88M | 15.68%-43.91M | -25.72%-70.14M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg